Population pharmacokinetics of long-term oral amiodarone therapy

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 6, 2000, Pages 642-652

  Pollak, P Timothy ^a,b,c   Bouillon, Thomas ^a,b   Shafer, Steven L ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b STANFORD UNIVERSITY   (United States)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

EID: 0034047520     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.107047     Document Type: Article

References (43)

1. 1. Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992;43:69-110.
2. 2. Pollak PT. Oral amiodarone: historical overview and development. Pharmacotherapy 1998;18:121S-6S.
3. 3. Flanagan RJ, Storey GC, Holt DW. Rapid high-performance liquid chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy. J Chromatogr 1980; 187:391-8.
4. 4. Andreasen F, Agerbaek H, Bjerregaard P, Gotzsche H. Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 1981;19:293-9.
5. 5. Anastasiou-Nana M, Levis GM, Moulopoulos S. Pharmacokinetics of amiodarone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 1982; 20:524-9.
6. 6. Riva E, Gerna M, Latini R, Giani P, Volpi A, Maggioni A. Pharmacokinetics of amiodarone in man. J Cardiovasc Pharmacol 1982;4:264-9.
7. 7. Kannan R, Nademanee K, Hendrickson JA, Rostami HJ, Singh BN. Amiodarone kinetics after oral doses. Clin Pharmacol Ther 1982;31:438-44.
8. 8. Haffajee CI, Love JC, Canada AT, Lesko LJ, Asdourian G, Alpert JS. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 1983;67:1347-55.
9. 9. Marchiset D, Aubert C, Sumirtapura YC, Egre A, Cano JP. Mass spectrometric identification of amiodarone N-monodesethyl metabolite and application of an HPLC method to a pharmacokinetic study. Eur J Drug Metab Pharmacokinet 1984;9:123-8.
10. 10. Staubli M, Bircher J, Galeazzi RL, Remund H, Studer H. Serum concentrations of amiodarone during long term therapy: relation to dose, efficacy and toxicity. Eur J Clin Pharmacol 1983;24:485-94.
11. 11. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J 1983;106:840-7.
12. 12. Plomp TA, van Rossum JM, Robles de Medina EO, van Lier T, Maes RA. Pharmacokinetics and body distribution of amiodarone in man. Arzneimittelforschung 1984;34:513-20.
13. 13. Riva E, Aarons L, Latini R, Neyroz P, Urso R. Amiodarone kinetics after single i.v. bolus and multiple dosing in healthy volunteers. Eur J Clin Pharmacol 1984;27: 491-4.
14. 14. Marchiset D, Bruno R, Djiane P, Cano JP, Benichou M, Serradimigni A. Amiodarone and desethylamiodarone elimination kinetics following withdrawal of long-term amiodarone maintenance therapy. Biopharm Drug Dispos 1985;6:209-15.
15. 15. Staubli M, Troendle A, Schmid B, Balmer P, Kohler B, Studer H, et al. Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. Eur J Clin Pharmacol 1985;29:417-23.
16. 16. Pollak PT, Sharma AD, Carruthers SG. Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. Am J Cardiol 1989;64:1138-43.
17. 17. Harris L, McKenna WJ, Rowland E, Holt DW, Storey GC, Krikler DM. Side effects of long-term amiodarone therapy. Circulation 1983;67:45-51.
18. 18. Echt DS, Liebson PR, Mitchell LB, Peters RW, ObiasManno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
19. 19. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990;82: 1106-16.
20. 20. Haverkamp W, Eckardt L, Borggrefe M, Breithardt G. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. Am J Cardiol 1997;80:67G-73G.
21. 21. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16: 1711-8.
22. 22. Greene HL. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J Cardiol 1993;72: 70F-4F.
23. 23. Janse MJ, Malik M, Camm AJ, Julian DG, Frangin GA, Schwartz PJ. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). Eur Heart J 1998;19:85-95.
24. 24. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493-8.
25. 25. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675-82.
26. 26. Singh BN. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 1997;20:608-18.
27. 27. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
28. 28. Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1998;81:995-8.
29. 29. Pollak PT. A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Ther Drug Monit 1996;18:168-78.
30. 30. Sheiner LB, Grasela TH. Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data. Drug Metab Rev 1984;15:293-303.
31. 31. Vozeh S, Wenk M, Follath F. Experience with NONMEM: analysis of serum concentration data in patients treated with mexiletine and lidocaine. Drug Metab Rev 1984;15:305-15.
32. 32. Sheiner BL, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters; II: Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981;9:635-51.
33. 33. Beal SL, Sheiner LB. NONMEM User's Guides. San Francisco: NONMEM Project Group, University of California; 1992.
34. 34. Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992;76:334-41.
35. 35. Youngs EJ, Shafer SL. Pharmacokinetic parameters relevant to recovery from opioids. Anesthesiology 1994;81: 833-42.
36. 36. Shafer SL. More on: improving the clinical utility of anesthetic drug pharmacokinetics [letter]. Anesthesiology 1992;77:608.
37. 37. Korth-Bradley JM, Rose GM, de Vane PJ, Peters J, Chiang ST. Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. J Clin Pharmacol 1996;36:715-9.
38. 38. Gaete LE, Ortiz M, Soto J, Saavedra I. [Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals]. Rev Med Chil 1995;123:713-9.
39. 39. Pourbaix S, Berger Y, Desager JP, Pacco M, Harvengt C. Absolute bioavailability of amiodarone in normal subjects. Clin Pharmacol Ther 1985;37:118-23.
40. 40. Nattel S, Talajic M. Recent advances in understanding the pharmacology of amiodarone. Drugs 1988;36:121-31.
41. 41. Daniels JM, Brien JF, Massey TE. Pulmonary fibrosis induced in the hamster by amiodarone and desethylamiodarone. Toxicol Appl Pharmacol 1989;100:350-359.
42. 42. Debbas NM, Du Cailar C, Sassine A, Derancourt J, Demaille JG, Puech P. Determination of cardiac and plasma drug levels during long-term amiodarone therapy. Eur J Clin Invest 1983;13:123-7.
43. 43. Siddoway LA, McAllister CB, Wilkinson GR, Roden DM, Woosley RL. Amiodarone dosing: a proposal based on its pharmacokinetics. Am Heart J 1983;106:951-6.